QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 poseida-therapeutics-highlights-interim-phase-1-results-for-p-bcma-allo1-and-preclinical-data-for-dual-car-t-p-cd19cd20-allo1-at-the-66th-ash-annual-meeting-additional-new-profiling-of-patient-responses-from-the-optimized-lymphodepletion-arm-show-consistent-p-bcma-allo1-cellular-expansion-and-persistence-across-subgroups

Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellu...

 btig-downgrades-poseida-therapeutics-to-neutral

BTIG analyst Justin Zelin downgrades Poseida Therapeutics (NASDAQ:PSTX) from Buy to Neutral.

 william-blair-downgrades-poseida-therapeutics-to-market-perform

William Blair analyst Raju Prasad downgrades Poseida Therapeutics (NASDAQ:PSTX) from Outperform to Market Perform.

 hc-wainwright--co-downgrades-poseida-therapeutics-to-neutral-lowers-price-target-to-9

HC Wainwright & Co. analyst Arthur He downgrades Poseida Therapeutics (NASDAQ:PSTX) from Buy to Neutral and lowers the p...

 roches-proposed-acquisition-of-poseida-therapeutics-poised-to-establish-new-core-capability-in-cell-therapy-for-cancer-and-autoimmune-diseases-details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic...

Core News & Articles

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-trade...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-q3-eps-021-beats-041-estimate-sales-7175m-beat-1627m-estimate

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of ...

 poseida-therapeutics-to-present-clinical-and-preclinical-data-on-investigational-allogeneic-car-t-cell-therapies-at-sitc-2024-and-ash-2024

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better targe...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-to-present-new-preclinical-data-supporting-non-viral-gene-editing-with-p-klkb1-101-for-the-treatment-of-hereditary-angioedema

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION